2025-12-28 - Analysis Report
Okay, here's a breakdown of the Visa (V) stock analysis, followed by a comprehensive summary.

**1. Comparative Return Analysis:**

*   **Ticker:** V (Visa Inc.) - A global payments technology company that connects consumers, businesses, banks, and governments, enabling them to use digital currency instead of cash and checks.
*   **Visa (V) Cumulative Return:** 58.15%
*   **S&P 500 (VOO) Cumulative Return:** 103.21%
*   **Divergence:** -45.3 (Meaning Visa has underperformed the S&P 500 by 45.3% cumulatively)
*   **Relative Divergence:** 13.0 (Suggests the current divergence is near the lower end of its historical range)

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 40.0% | 67.1% | 11.0% | 0.0 | 220.1 |
| 2016-2018  | 25.0% | 71.8% | 9.0% | 0.2 | 254.6 |
| 2017-2019  | 45.0% | 71.8% | 23.0% | 0.3 | 362.6 |
| 2018-2020  | 16.0% | 81.4% | -8.0% | 0.4 | 422.1 |
| 2019-2021  | 12.0% | 81.4% | -34.0% | 0.7 | 418.2 |
| 2020-2022  | -37.0% | 81.4% | -37.0% | 1.0 | 401.0 |
| 2021-2023  | -15.0% | 80.5% | -16.0% | 1.1 | 502.4 |
| 2022-2024  | 16.0% | 80.5% | -5.0% | 1.1 | 609.9 |
| 2023-2025  | 25.0% | 80.4% | -43.0% | 0.7 | 685.1 |

**Analysis:** Visa has significantly underperformed the S&P 500 over the provided period. The Alpha figures are negative in recent years, indicating underperformance relative to its risk (as measured by Beta). The Beta values have generally increased, suggesting that Visa's stock price is becoming more sensitive to market movements.  The Maximum Drawdown (MDD) is consistently high, indicating significant potential for loss.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 355.0
*   **Last Market Data:** Price: 355.0, Previous Close: 355.14, Change: -0.04
*   **5-day SMA:** 352.97
*   **20-day SMA:** 340.44
*   **60-day SMA:** 339.98

**Analysis:** The stock price is currently slightly below its previous close. The 5-day SMA is above both the 20-day and 60-day SMAs, suggesting a short-term upward trend.  The 20-day and 60-day SMAs are very close, indicating price consolidation around that level.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 1.0 (High Investment Recommended)
*   **RSI:** 78.35 (Overbought)
*   **PPO:** 0.592
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (3 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 0.5 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** -92.8%

**Analysis:** The MRI suggests a high investment recommendation. However, the RSI is in overbought territory, signaling a potential pullback. The recent relative divergence change indicates short-term upward momentum. The significantly negative expected return is a major concern, suggesting long-term underperformance compared to the S&P 500.

**4. Recent News & Significant Events:**

*   **Positive Headlines:** Articles highlight Visa's high margins, a potential buying opportunity due to a discount, and reasons for recent stock price increases.
*   **General Market News:** Articles discuss broader market trends, comparisons between Amazon and Microsoft, and quantum computing stocks.
*   **Company Specific:**  Mentions a dividend hike, stablecoin push, and forecasts for 2026-2030.
*   **Irrelevant Headline:** The Inspire Medical Systems headline is unrelated.

**4.2 Analyst Opinions**

*   **Consensus:** Strong Buy
*   **Mean Rating:** 1.50 (Between Strong Buy and Buy)
*   **Number of Opinions:** 37
*   **Target Price:** Average: 395.85, High: 450.00, Low: 305.00
*   **Recent Rating Changes:** No changes.

**Analysis:** Analyst sentiment is strongly positive, with a consensus "Strong Buy" rating and an average target price suggesting significant upside potential.

**5. Comprehensive Analysis:**

Visa has significantly underperformed the S&P 500 recently, as reflected in the negative divergence and Alpha figures. While recent news articles present some positive aspects like high margins and potential growth areas (stablecoins), the technical indicators paint a mixed picture. The MRI suggests it's a good time to invest, but the RSI indicates the stock may be overbought. The strongly negative expected return raises a significant red flag about long-term investment prospects *relative to the S&P 500*.

The analyst consensus is overwhelmingly positive, with a strong buy rating and an average target price that is substantially higher than the current trading price. However, the technical indicators and the significant underperformance relative to the S&P 500 should give potential investors pause.

**In Summary:**

Visa appears to be a company with strong analyst support and some positive catalysts on the horizon. However, its recent underperformance, high RSI, and negative expected return compared to the S&P 500 suggests that caution is warranted. Investors should carefully weigh the positive analyst sentiment against the negative technical indicators and historical underperformance before making a decision.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.